Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004200 · ClinicalTrials.gov registry record · Phase 2
Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004200 is a Phase 2 study that has completed, run by Pfizer.
The verdict
NCT00004200, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Prinomastat may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of prinomastat plus temozolomide in treating patients who have newly diagnosed glioblastoma multiforme.
Interventions
- DRUG temozolomide
- DRUG prinomastat
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004200
The ClinicalTrials.gov registry entry for NCT00004200 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which temozolomide is the first listed.
NCT00004200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004200 about?
NCT00004200 is a clinical study titled "Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". RATIONALE: Prinomastat may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of prinomastat plus temozolomide in treatin...
What is the current status of trial NCT00004200?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-10.
What interventions are being tested in trial NCT00004200?
The interventions under investigation include: temozolomide (DRUG), prinomastat (DRUG).
Who is sponsoring clinical trial NCT00004200?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.